While insiders own 20% of Galectin Therapeutics Inc. (NASDAQ:GALT), individual investors are its largest shareholders with 54% ownership [Yahoo! Finance]
Galectin Therapeutics Inc. (GALT)
Last galectin therapeutics inc. earnings: 11/12 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.galectintherapeutics.com/investor-relations
Company Research
Source: Yahoo! Finance
A total of 25 investors have a majority stake in the company with 44% ownership Insiders have bought recently A look at the shareholders of Galectin Therapeutics Inc. ( NASDAQ:GALT ) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are individual investors with 54% ownership. Put another way, the group faces the maximum upside potential (or downside risk). Meanwhile, individual insiders make up 20% of the company's shareholders. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Let's take a closer look to see what the different types of shareholders can tell us about Galectin Therapeutics. See our latest analysis for Galectin Therapeutics NasdaqCM:GALT Ownership Breakdown March 8th 2025 What Does The Institutional Ownership Tell Us About Galectin Therapeutics? Many institutions measure their performance against an index that approximate
Show less
Read more
Impact Snapshot
Event Time:
GALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GALT alerts
High impacting Galectin Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GALT
News
- Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains [Seeking Alpha]Seeking Alpha
- Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line [Yahoo! Finance]Yahoo! Finance
- Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 [Yahoo! Finance]Yahoo! Finance
- Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027GlobeNewswire
- Galectin Therapeutics (NASDAQ:GALT) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
GALT
Analyst Actions
- 12/17/25 - HC Wainwright
GALT
Sec Filings
- 12/23/25 - Form 4/A
- 12/23/25 - Form 4/A
- 12/23/25 - Form 4
- GALT's page on the SEC website